GenScript unit Legend Biotech to present updated long-term CARVYKTI CARTITUDE-2 data at IMS meeting

LEGN•2026-09-10

Updated CARVYKTI data scheduled for IMS 2026

GenScript Biotech’s Legend Biotech unit flagged updated long-term data for CARVYKTI from the CARTITUDE-2 program at IMS 2026.

Results will be presented September 23-26, 2026, with a focus on earlier-line, lenalidomide-refractory multiple myeloma.

The update highlights durable remission and survival signals in CARTITUDE-2 Cohort A, supporting CARVYKTI’s positioning beyond late-line use.

Additional posters will cover real-world outcomes and an early readout from a post-authorization safety study, aimed at validating performance in routine care.

GenScript unit Legend Biotech to present updated long-term CARVYKTI CARTITUDE-2 data at IMS meeting

Updated CARVYKTI data scheduled for IMS 2026

Related News

Worksport announces shareholder CEO town hall meeting

Acorn Energy OmniMetrix buys Gen-Tracker generator monitoring assets for $3.5 million

SEI research finds 71% of wealthy investors say advisors never ask to manage more assets

Macy's falls as downbeat quarterly view clouds annual forecast boost

DoorDash partners with Locally to add specialty retailers to marketplace